| Previous Close | 0.045 |
| Open | 0.045 |
| Bid | 0.045 x |
| Ask | 0.050 x |
| Day's Range | 0.045 - 0.045 |
| 52 Week Range | 0.030 - 0.090 |
| Volume | 194,181 |
| Avg. Volume | 359,049 |
| Market Cap | 3.8M |
| Beta | 3.71 |
| PE Ratio (TTM) | -3.75 |
| EPS (TTM) | -0.01 |
| Earnings Date | Nov 26, 2015 - Nov 30, 2015 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- Newsfile•20 days ago
iCo Therapeutics Announces Election of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the election of directors at the annual meeting of shareholders held on June 29, 2017. At the annual meeting of shareholders held on June 29, 2017, Andrew Rae, Susan Koppy, Wiiliam Jarosz and Michael Liggett were elected directors of the Company and will hold office until the next annual general meeting ...
- EQS Group•last month
iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous15.06.2017 / 22:15 The issuer is solely responsible for the content of this announcement.
- Newsfile•last month
iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a ...
